Browsing Tag
inflammation
2 posts
Will Biogen’s $1bn bet on Vanqua Bio’s oral inflammation drug jumpstart its post-MS future?
Biogen’s $1.06B Vanqua Bio licensing deal signals a strategic shift toward immunology. Explore the roadmap behind this bold preclinical move.
Nasdaq: KOD — Is Kodiak Sciences’ KSI-101 finally turning Wall Street bullish on ocular inflammation?
Explore how Kodiak Sciences’ KSI‑101 is reshaping the retinal‑disease treatment landscape and why JPMorgan just upgraded the stock—read more now!